<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>With the increasing number of available predictive biomarkers, clinical management of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is becoming increasingly reliant on the accurate serial monitoring of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> genotypes </plain></SENT>
<SENT sid="1" pm="."><plain>We tested whether <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific copy number changes can be inferred from the peripheral blood of patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To this end, we determined the plasma DNA size distribution and the fraction of mutated plasma DNA fragments with deep sequencing and an ultrasensitive mutation-detection method, i.e., the Beads, Emulsion, Amplification, and Magnetics (BEAMing) assay </plain></SENT>
<SENT sid="3" pm="."><plain>When analyzing the plasma DNA of 32 patients with Stage IV colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp>, we found that a subset of the patients (34.4%) had a biphasic size distribution of plasma DNA fragments that was associated with increased circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell numbers and elevated concentration of mutated plasma DNA fragments </plain></SENT>
<SENT sid="4" pm="."><plain>In these cases, we were able to establish genome-wide <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific copy number alterations directly from plasma DNA </plain></SENT>
<SENT sid="5" pm="."><plain>Thus, we could analyze the current copy number status of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> genome, which was in some cases many years after diagnosis of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>An unexpected finding was that not <z:hpo ids='HP_0000001'>all</z:hpo> patients with progressive <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> appear to release <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> DNA into the circulation in measurable quantities </plain></SENT>
<SENT sid="7" pm="."><plain>When we analyzed plasma DNA from 35 patients with metastatic <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, we made similar observations suggesting that our approach may be applicable to a variety of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> entities </plain></SENT>
<SENT sid="8" pm="."><plain>This is the first description of such a biphasic distribution in a surprisingly high proportion of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients which may have important implications for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> diagnosis and monitoring </plain></SENT>
</text></document>